Oncology Accounting Software

Accounting in a Oncology Practice

A medical oncology practice runs a pharmacy inside its books. Under buy-and-bill, the practice buys chemotherapy, immunotherapy and supportive drugs, holds them in stock, mixes each dose, and bills after it is given. Oncology accounting software follows each drug through those steps. Purchases come in at cost. Each compounded dose is matched to the order and the claim line that billed it, and any waste is matched to its JW line. Vials used but not billed show up each day, not at the yearly count. Payment on each drug line is set against its cost, so the margin by drug, payer and site is known. Contract rates are checked against purchase price, and a warning is raised when a payer pays less than the drug costs. Revenue, adjustments and cost of goods export to the general ledger as journal entries.

Why Is Accounting Different in Oncology?

Drug cost is the largest line on the books, and the payment side moves every quarter. Medicare pays most Part B drugs from an average sales price limit that CMS resets each quarter, while the practice's own cost depends on its purchase terms. A drug that made money last quarter can lose money this one. Accounting that only sees totals at month end finds the loss after many doses have been given.

Stock and claims have to agree. Every vial that leaves the shelf should end up as a billed dose, a billed JW waste line, or a documented loss. When the pharmacy log and the claims are kept apart, gaps hide until the yearly count. Daily matching of what was mixed against what was billed keeps that gap small, and it gives auditors a clear trail from purchase to payment.

Some revenue doesn't come from a single claim. Practices in the Enhancing Oncology Model receive monthly M0010 payments and, later, a payment or a repayment based on cost and quality over each episode. Practices with 340B sites, or with several locations, also need drug cost kept by site. Accounting for oncology has to hold these streams apart and still close the month on one set of books, with the episode side tied to value-based care tracking.

What Oncology Accounting Software Handles

ASP payment limits each quarter

Most separately payable Part B drugs pay at ASP plus a set add-on, and CMS publishes new limits every quarter. Drug margins are recalculated when each new file takes effect, so a drug that slips below cost is seen in the quarter it happens. (CMS: Medicare Part B Drug Average Sales Price)

NDC to HCPCS crosswalk

CMS posts an NDC-to-HCPCS crosswalk next to each year's payment limit files. Purchases are kept by NDC and billing by HCPCS unit, and the crosswalk links the two so cost per billed unit can be worked out. (CMS: Medicare Part B Drug Payment Limit Files and NDC-HCPCS crosswalks)

Qualifying biosimilar add-on

Under the Inflation Reduction Act, qualifying biosimilars are paid with a higher add-on, based on the reference product's ASP, for a five-year period. Margin reports show the biosimilar and its reference product side by side, so buying choices reflect the real payment. (CMS: Inflation Reduction Act FAQs, Medicare Part B payment for qualifying biosimilars)

JW waste and JZ attestation

Under Medicare Part B, discarded drug from a single-dose container is billed with JW, and JZ attests that none was discarded. The modifiers come from the compounding record, so billed waste matches what the pharmacy logged. (CMS: Discarded Drugs and Biologicals (JW and JZ modifiers))

340B units and the TB modifier

Since 2025, 340B covered entities report the TB modifier on Medicare Part B claims for 340B-acquired drugs. Where a site is part of a 340B covered entity, staff can use that site's cost center and a report to keep its drug cost and drug lines apart from other sites. (CMS MLN4800856: Medicare Part B Inflation Rebate Guidance, Use of the 340B Modifier)

EOM performance-based payments

EOM practices share savings when spending stays below target and quality is met, and repay part of the excess when spending runs over. Expected payments or repayments are tracked in the ledger, so the close is not hit by surprise. (CMS Innovation Center: Enhancing Oncology Model)

How Does Oncology Accounting Software Work?

1. 1. Book purchases at cost

   Drug invoices are entered by NDC with quantity and price. Stock on hand is valued at what the practice paid.

2. 2. Match doses to claims

   Each compounded dose is matched to its order and the claim line that billed it. Waste is matched to its JW line, and vials with no claim are flagged each day.

3. 3. Check contract rates before giving

   Contract and ASP rates are compared with purchase price for each drug. If a payer pays less than cost, a warning shows before the dose is prepared.

4. 4. Post payments and cost of goods

   Payments and adjustments flow in from oncology payment posting. Revenue and cost of goods for each drug line post as balanced entries.

5. 5. Close and export

   Journal entries export to the general ledger or ERP by cost center, such as provider and location. Month-end close starts from numbers that already match the claims.

Oncology Accounting Software vs. Generic Software

Who Uses It in a Oncology Practice

• Controller: Journal entries that already match posted payments and drug cost, so the close is review, not rework.
• Pharmacy manager: A daily list of vials used but not billed, and margin by drug to bring to buying talks.
• Physician owner: Margin by drug, payer and site, with EOM payments and 340B sites reported apart by cost center, so the practice knows where it really makes money.